Federated Hermes Reports 10.54M Shares (10.76%) of aTyr Pharma
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class.
Rhea-AI Filing Summary
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
Positive
- Material passive stake disclosed: 10,544,437 shares representing 10.76%
- Clear intent statement: Securities stated as held in the ordinary course and not for control
- Required exhibits provided: Joint-filing agreement and power of attorney attached
Negative
- None.
Insights
Federated Hermes reports a meaningful passive stake of 10.76%.
The ownership position totals 10,544,437 shares and is presented as held in the ordinary course of business with sole voting and dispositive power reported for Federated Hermes and shared power reflected for certain trustees and individuals.
This level of ownership is material to investors because it crosses the 5% reporting threshold and may affect liquidity and block-trade dynamics; monitor any subsequent amendments or Schedule 13D filings for changes in intent or coordination within 30/09/2025–10/07/2025.
Filing asserts non-control intent and supplies required joint-filing exhibits.
The certification states the securities were not acquired to influence control, and Exhibits include an agreement for joint filing and a power of attorney, which clarifies the administrative and voting arrangements among reporting persons.
Investors should note the formal declaration of passive intent and the attached exhibits; any future change in that declaration or additional coordination among reporting persons would be the next material governance signal to watch over the coming quarters.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of aTyr Pharma does the reported stake represent?
Does the filing indicate an intent to influence control of aTyr Pharma (ATYR)?
Who else is named as a reporting person in the Schedule 13G/A?
What exhibits are included with this Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.